Aurobindo Pharma Ltd posted a consolidated net loss of Rs 80 crore (Rs 198 crore net profit) in the second quarter ended September 30, 2011. Net sales declined to Rs 960 crore (Rs 1050 crore).
The loss was mainly due to an exchange fluctuation loss or Rs 185 crore, among other factors.
“The first half of the current fiscal has been challenging on account of lower formulation sales, and full impact of the US Food and Drug Administration alert on our Unit VI Cephalosporin manufacturing facility,” Mr Ramprasad Reddy, Chairman, Aurobindo Pharma said in a release issued here on Tuesday.
The disruption in operations due to regional unrest and notional loss on restatement of foreign currency borrowings, also impacted, he added.
During the quarter, the company filed seven Abbreviated New Drug Applications in the US and 50 dossier filings in Europe.
Its step-down subsidiary, Aurobindo Pharma (Bulgaria) EAD was liquidated and ceased to be a subsidiary.
Aurobindo Pharma's scrip declined 4 per cent to end at Rs 123.25 on the Bombay Stock Exchange on Tuesday.